Attached files
file | filename |
---|---|
8-K - FORM 8-K - IntelGenx Technologies Corp. | form8k.htm |
IntelGenx Announces Development and Commercialization
Agreement with Endo Ventures
Saint-Laurent, Canada December 27, 2016 – IntelGenx Corp., (TSXV: IGX) (OTCQX: IGXT), today announced that it has entered into a co-development and commercialization agreement with Endo Ventures Ltd. (Endo) for a new product utilizing IntelGenx’ proprietary VersaFilmTM for the USA market.
Under the agreement, Endo has obtained certain exclusive rights to market and sell IntelGenx product in the USA. IntelGenx will receive an upfront payment and future milestone payments. Endo and IntelGenx will share the profits of commercialization.
We are thrilled to further strengthen our partnership with such a significant global pharmaceutical organization as Endo, said Dr. Horst Zerbe, President and CEO of IntelGenx. We see the completion of this deal as further validation of our VersaFilmTM technology and our ability to enter into high quality partnerships. IntelGenx continues to make tremendous progress in executing our strategy of becoming a global leader in pharmaceutical oral films.
About IntelGenx:
IntelGenx is a leading oral drug delivery company primarily
focused on the development and manufacturing of innovative pharmaceutical oral
films based on its proprietary VersaFilmTM technology platform.
Established in 2003, the Montreal-based company is listed on the TSX-V and
OTC-QX.
IntelGenx highly skilled team provides comprehensive
pharmaceuticals services to pharmaceutical partners, including
R&D, analytical method development, clinical monitoring, IP and regulatory
services. IntelGenx state-of-the-art manufacturing facility, established for the
VersaFilmTM technology platform, supports lab-scale to pilot and
commercial-scale production, offering full service capabilities to our clients.
More information is available about the company at: www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking information about
IntelGenx' operating results and business prospects that involve substantial
risks and uncertainties. Statements that are not purely historical are
forward-looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933,
as amended. These statements include, but are not limited to, statements about
IntelGenx' plans, objectives, expectations, strategies, intentions or other
characterizations of future events or circumstances and are generally identified
by the words "may," "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates," "could," "would," and similar expressions. All forward
looking statements are expressly qualified in their entirety by this cautionary
statement. Because these forward-looking statements are subject to a number of
risks and uncertainties, IntelGenx' actual results could differ materially from
those expressed or implied by these forward looking statements. Factors that
could cause or contribute to such differences include, but are not limited to,
those discussed under the heading "Risk Factors" in IntelGenx' annual report on
Form 10-K, filed with the United States Securities and Exchange Commission and
available at www.sec.gov, and also filed with Canadian securities
regulatory authorities and www.sedar.com. IntelGenx assumes no
obligation to update any such forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
For more information, please contact:
Edward
Miller
Director, IR and Corporate Communications
IntelGenx Corp.
T:
+1 514-331-7440 (ext. 217)
edward@intelgenx.com